-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $83

Benzinga·09/18/2026 10:39:59
语音播报
B. Riley Securities analyst Mayank Mamtani initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and announces Price Target of $83.